Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.
Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management
Revisit the OncLive On Air Episodes From February 2024
The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma